Elvina Almuradova/LinkedIn
Feb 8, 2025, 13:29
Elvina Almuradova: FIRE-4 Trial Confirms the Clinical Relevance of Liquid Biopsy in mCRC
Elvina Almuradova, Oncology Unit Lead at Can Hospitals Turkey, shared a post on LinkedIn:
“FIRE-4 Trial Confirms the Clinical Relevance of Liquid Biopsy in Metastatic Colorectal Cancer!!!
New findings from the phase III FIRE-4 trial, published JCO confirm that liquid biopsy accurately identifies RAS/BRAF V600E mutations in metastatic colorectal cancer (mCRC), offering critical insights before treatment.
– Accurate Molecular Profiling: Liquid biopsy aligns with tissue-based analysis.
– Impact on Survival: RAS-mutant patients had shorter PFS and OS.
– Treatment Insights: Early switch maintenance therapy benefited RAS-mutant patients.
– Tumor Evolution: Higher RAS mutation conversion with continuous cetuximab.”
Read full article at the ASCO Post.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 8, 2025, 13:24
Feb 8, 2025, 12:46
Feb 8, 2025, 12:19
Feb 8, 2025, 12:17
Feb 8, 2025, 12:07
Feb 8, 2025, 12:06